Profile data is unavailable for this security.
About the company
Procter & Gamble Health Limited is an India-based company that is primarily engaged in the manufacturing of pharmaceutical products. The Company is engaged in the manufacturing and marketing of over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle. The Company’s brands include Cosome, Evion, Neurobion, Seven Seas, Nasivion, Polybion, and Livogen. Cosome is a medicine which is used to help relieve dry coughs and related congestion symptoms. Evion is a Vitamin E capsules. The Evion range has different variants with different levels of Vitamin E, such as Evion 400, Evion 200, and Evion 600. Neurobion offers a range of neurotropic B-Vitamins which are a combination to help treat nerve damage and regenerate the nerves to relieve symptoms. Nasivion Classic Nasal Spray starts working on a blocked nose in 25 seconds. Polybion is a brand that helps with release and hence supports an active life.
- Revenue in INR (TTM)11.69bn
- Net income in INR2.14bn
- Incorporated1967
- Employees1.41k
- LocationProcter & Gamble Health LtdGodrej One,8Th Floor Pirojshanagar, Vikhroli (East)MUMBAI 400079IndiaIND
- Phone+91 2 262109000
- Fax+91 2 262109999
- Websitehttps://www.pghealthindia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Advanced Enzyme Technologies Ltd | 6.05bn | 1.37bn | 43.97bn | 338.00 | 32.03 | -- | 25.33 | 7.27 | 12.28 | 12.28 | 54.16 | -- | -- | -- | -- | 17,892,400.00 | -- | 11.87 | -- | 13.19 | 76.42 | 72.20 | 23.02 | 25.79 | -- | 59.04 | -- | 7.49 | 2.13 | 6.44 | -11.66 | 3.24 | 28.32 | 14.87 |
| Aarti Pharmalabs Ltd | 18.32bn | 1.95bn | 45.74bn | 1.40k | 23.51 | -- | 17.29 | 2.50 | 21.47 | 21.47 | 202.17 | -- | -- | -- | -- | 13,085,090.00 | -- | -- | -- | -- | 42.00 | -- | 10.62 | -- | -- | 16.14 | -- | -- | 62.11 | -- | 58.27 | -- | -- | -- |
| Shilpa Medicare Ltd | 11.23bn | -6.71m | 50.06bn | 1.03k | -- | -- | 47.08 | 4.46 | -0.0714 | -0.0714 | 131.44 | -- | -- | -- | -- | 10,873,050.00 | -- | 3.89 | -- | 4.92 | 64.42 | 60.22 | -0.0538 | 9.29 | -- | 1.16 | -- | 10.65 | -8.33 | 5.82 | -153.54 | -- | 14.58 | -- |
| Orchid Pharma Ltd | 8.12bn | 1.25bn | 52.36bn | 838.00 | 36.23 | -- | 32.94 | 6.45 | 28.50 | 26.84 | 175.33 | -- | -- | -- | -- | 9,691,729.00 | -- | -1.07 | -- | -1.96 | 41.49 | 45.87 | 15.63 | -3.52 | -- | 4.34 | -- | -- | 19.00 | -0.6456 | 187.87 | -- | 68.72 | -- |
| Blue Jet Healthcare Ltd | -100.00bn | -100.00bn | 65.76bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.49 | -- | -11.88 | -- | -- | -- |
| Sun Pharma Advanced Research Co Ltd | 1.07bn | -3.63bn | 71.49bn | 407.00 | -- | -- | -- | 67.02 | -11.22 | -11.22 | 3.29 | -- | -- | -- | -- | 2,621,133.00 | -- | -59.13 | -- | -119.29 | 75.21 | 79.70 | -340.66 | -116.46 | -- | -400.34 | -- | -- | 73.98 | 25.00 | -9.43 | -- | -13.96 | -- |
| Marksans Pharma Ltd | 21.03bn | 3.17bn | 72.30bn | 1.40k | 22.64 | -- | 18.68 | 3.44 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
| F D C Ltd | 19.16bn | 2.90bn | 73.54bn | 6.37k | 25.63 | -- | 22.38 | 3.84 | 17.63 | 17.63 | 116.59 | -- | -- | -- | -- | 3,006,457.00 | -- | 11.68 | -- | 13.29 | 65.72 | 62.03 | 15.11 | 15.85 | -- | 70.61 | -- | 1.22 | 16.74 | 10.49 | -10.34 | 2.26 | 25.03 | -- |
| Strides Pharma Science Ltd | 39.53bn | -1.52bn | 76.37bn | 2.85k | -- | -- | 129.10 | 1.93 | -16.88 | -10.96 | 436.72 | -- | -- | -- | -- | 13,871,790.00 | -- | -0.9448 | -- | -1.59 | 58.90 | 49.75 | -4.37 | -2.19 | -- | 0.9061 | -- | -- | 20.13 | 5.33 | 51.93 | -- | -25.10 | -5.59 |
| Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 78.75bn | 1.41k | 36.82 | -- | 32.71 | 6.74 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
| Wockhardt Ltd | 27.76bn | -5.01bn | 83.53bn | 2.74k | -- | -- | -- | 3.01 | -34.79 | -34.79 | 192.79 | -- | -- | -- | -- | 10,131,390.00 | -- | -4.12 | -- | -7.34 | 57.60 | 53.98 | -19.16 | -10.98 | -- | -0.1981 | -- | -- | -17.93 | -7.60 | -129.10 | -- | -7.43 | -- |
| Neuland Laboratories Ltd. | 15.81bn | 3.17bn | 95.68bn | 1.57k | 30.18 | -- | 25.60 | 6.05 | 247.14 | 247.14 | 1,232.07 | -- | -- | -- | -- | 10,048,590.00 | -- | 5.69 | -- | 7.95 | 51.76 | 43.56 | 20.06 | 8.07 | -- | 28.54 | -- | 8.27 | 25.25 | 17.62 | 156.21 | 68.43 | -13.12 | -- |
| Caplin Point Laboratories Ltd | 16.30bn | 4.38bn | 98.63bn | 777.00 | 22.66 | -- | 20.15 | 6.05 | 57.33 | 57.33 | 213.53 | -- | -- | -- | -- | 20,980,180.00 | -- | 21.04 | -- | 24.25 | 56.48 | 52.84 | 27.08 | 25.02 | -- | 845.56 | -- | 9.37 | 15.54 | 22.13 | 25.49 | 21.05 | 31.87 | 17.61 |
| Granules India Ltd | 45.26bn | 3.95bn | 99.58bn | 3.65k | 25.18 | -- | 16.65 | 2.20 | 16.32 | 16.32 | 186.88 | -- | -- | -- | -- | 12,400,240.00 | -- | 11.15 | -- | 16.55 | 51.94 | 49.35 | 8.73 | 12.39 | -- | 6.53 | -- | 10.08 | 19.84 | 21.67 | 25.16 | 31.26 | -1.66 | 8.45 |
| Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 102.97bn | 1.82k | 21.90 | 4.41 | 19.64 | 4.51 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Jubilant Pharmova Ltd | 66.22bn | 378.60m | 110.51bn | 1.03k | 287.99 | -- | 18.85 | 1.67 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
Data as of May 09 2024. Currency figures normalised to Procter & Gamble Health Ltd's reporting currency: Indian Rupee INR
16.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Sep 2023 | 596.81k | 3.60% |
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 2023 | 399.97k | 2.41% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Mar 2024 | 393.13k | 2.37% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Sep 2023 | 338.85k | 2.04% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Mar 2024 | 281.87k | 1.70% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 273.28k | 1.65% |
| The New India Assurance Co. Ltd. (Investment Portfolio)as of 30 Sep 2022 | 166.55k | 1.00% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 120.36k | 0.73% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 99.73k | 0.60% |
| Sundaram Asset Management Co. Ltd.as of 31 Mar 2024 | 78.24k | 0.47% |
More ▼
Data from 31 Dec 2023 - 02 May 2024Source: FactSet Research Systems Inc.
